Suppr超能文献

粪便微生物群移植的输送途径:现有的、预期的和渴望的。

Delivery routes for faecal microbiota transplants: Available, anticipated and aspired.

机构信息

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.

出版信息

Pharmacol Res. 2020 Sep;159:104954. doi: 10.1016/j.phrs.2020.104954. Epub 2020 May 31.

Abstract

Fecal microbiota transplant (FMT) has seen a historic emergence in last decade with its sojourn recently entering into a chequered path, due to a few reports of infection and subsequent mortality. Though FMT has been extensively reported, there is no comprehensive report on the delivery routes available for this non-pharmacological treatment option. Safety, efficacy and cost of FMT not only depend on the quality of contents but also on the delivery route employed. A number of delivery routes are in use for conducting FMT, which include upper gastrointestinal routes (UGI) i.e. nasogastric/nasojejunal tube, endoscopy, oral capsules and lower gastrointestinal routes (LGI) like retention enema, sigmoidoscopy or colonoscopy. Capsules, both conventional as well as colon targeted have been the most commonly used formulations. Surprisingly, the success rates with conventional gastric delivery capsules and colon targeted capsules were found to be quite similar indicating the sufficiency of the inoculum size to withstand the microbial loss in the gastric milieu. Patient compliance, cost effectiveness, comfort of administration, level of invasiveness, patient's hospital admission, risk of aspiration and infections, multiplicity of administration required, recurrence rate are the main factors that seem to influence the choice for route of administration of physicians. The best route for FMT has not been established yet. Extensive studies are required to understand the interplay of route adopted, type of donor, physical nature of sample (fresh or frozen), patient compliance and cost effectiveness to design an approach for the risk free, convenient and cost-effective administration route for FMT.

摘要

粪便微生物移植(FMT)在过去十年中得到了历史性的发展,但由于少数感染和随后死亡的报告,其最近的发展进入了一个曲折的道路。尽管 FMT 已经被广泛报道,但对于这种非药物治疗选择的可用输送途径,尚无综合报告。FMT 的安全性、疗效和成本不仅取决于内容的质量,还取决于所采用的输送途径。有许多输送途径可用于进行 FMT,包括上胃肠道途径(UGI),即鼻胃/鼻空肠管、内窥镜检查、口服胶囊和下胃肠道途径(LGI),如保留灌肠、乙状结肠镜或结肠镜检查。胶囊,包括常规和结肠靶向的,是最常用的制剂。令人惊讶的是,发现常规胃输送胶囊和结肠靶向胶囊的成功率相当相似,这表明接种物的大小足以承受胃环境中的微生物损失。患者的依从性、成本效益、给药的舒适度、侵袭性水平、患者住院、吸入和感染的风险、所需给药的次数、复发率是影响医生选择给药途径的主要因素。FMT 的最佳途径尚未确定。需要进行广泛的研究,以了解所采用的途径、供体类型、样本的物理性质(新鲜或冷冻)、患者的依从性和成本效益之间的相互作用,从而设计一种安全、方便且具有成本效益的 FMT 给药途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验